Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
EGFR expression
Description:
The presence or level of epidermal growth factor receptor, a cell-surface protein, in tissues or cells, often studied in cancer biology.
Related topics:
Lung Cancer Treatments and Mutations (18%),
HER2/EGFR in Cancer Research (10%),
Head and Neck Cancer Studies (10%),
Colorectal Cancer Treatments and Studies (8%)
OpenAlex ID:
keywords/egfr-expression
EGFR and cancer prognosis
2001
·
R.I Nicholson
, J.M.W Gee
, et al.
·
European Journal of Cancer
·
2,205
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
2007
·
Eric Van Cutsem
, Marc Peeters
, et al.
·
Journal of Clinical Oncology
·
2,011
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005
·
Ming-Sound Tsao
, Akira Sakurada
, et al.
·
New England Journal of Medicine
·
1,836
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
2011
·
Masahiro Fukuoka
, Yi-Long Wu
, et al.
·
Journal of Clinical Oncology
·
1,613
Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study
2005
·
Barbara Burtness
, Meredith A. Goldwasser
, et al.
·
Journal of Clinical Oncology
·
889
Stem Cell–Related “Self-Renewal” Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma
2008
·
Anastasia Murat
, Eugenia Migliavacca
, et al.
·
Journal of Clinical Oncology
·
741
PDF
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
2015
·
Scott Kopetz
, Jayesh Desai
, et al.
·
Journal of Clinical Oncology
·
721
PDF
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer
2006
·
Fred R. Hirsch
, Marileila Varella-Garcia
, et al.
·
Journal of Clinical Oncology
·
705
PDF
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
2015
·
Matthew J. Niederst
, Lecia V. Sequist
, et al.
·
Nature Communications
·
673
PDF
EGFR, p16, HPV Titer, Bcl-xL and p53, Sex, and Smoking As Indicators of Response to Therapy and Survival in Oropharyngeal Cancer
2008
·
Bhavna Kumar
, Kitrina G. Cordell
, et al.
·
Journal of Clinical Oncology
·
618
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
2011
·
Robert Pirker
, Jose R Pereira
, et al.
·
The Lancet Oncology
·
591
In vivo wound healing of diabetic ulcers using electrospun nanofibers immobilized with human epidermal growth factor (EGF)
2007
·
Ji Suk Choi
, Kam W. Leong
, et al.
·
Biomaterials
·
530
Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer
2005
·
Philip A. Philip
, Michelle R. Mahoney
, et al.
·
Journal of Clinical Oncology
·
468
Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines
2007
·
Jun Kurai
, Hiroki Chikumi
, et al.
·
Clinical Cancer Research
·
448
PDF
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
2017
·
Ken Uchibori
, Naohiko Inase
, et al.
·
Nature Communications
·
441
PDF
Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib
2012
·
Elizabeth A. Punnoose
, Siminder Atwal
, et al.
·
Clinical Cancer Research
·
428
Combined analysis of HPV‐DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer
2007
·
Niklas Reimers
, Hans U. Kasper
, et al.
·
International Journal of Cancer
·
427
PDF
IncreasedHER2Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer Patients
2005
·
Federico Cappuzzo
, Marileila Varella-Garcia
, et al.
·
Journal of Clinical Oncology
·
368
PDF
Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas.
1999
·
T Akimoto
, N R Hunter
, et al.
·
PubMed
·
357
The epidermal growth factor receptor and the prognosis of bladder cancer
1990
·
David E. Neal
, Linda Sharples
, et al.
·
Cancer
·
346
PDF
Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis.
1994
·
D M Shin
, J Y Ro
, et al.
·
PubMed
·
326
Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial
2007
·
E. Van Cutsem
, M. Nowacki
, et al.
·
Journal of Clinical Oncology
·
311
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
2004
·
U. Gatzemeier
, A. Pluzanska
, et al.
·
Journal of Clinical Oncology
·
311
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
2007
·
Melanie B. Thomas
, Romil Chadha
, et al.
·
Cancer
·
310
Molecular Biomarker Analyses Using Circulating Tumor Cells
2010
·
Elizabeth A. Punnoose
, Siminder K. Atwal
, et al.
·
PLoS ONE
·
298
PDF
Show more works
View as search
Works count:
2,402
Citation count:
55,880
Year
Topic
Type